Quick answer: The leading AI patent drafting platforms in 2026 fall into two categories — end-to-end lifecycle platforms that combine drafting with prior art search, prosecution, and invalidity analysis (e.g., XLSCOUT, Patlytics, PatSnap), and focused drafting tools built primarily to...
AI patent drafting tools now generate first-pass claims, abstracts, descriptions, and drawings from an invention disclosure, cutting the most time-intensive stage of the patent lifecycle. These drafts are built for attorney review, not blind filing. XLSCOUT’s Drafting LLM produces comprehensive...
Introduction In US biotech and pharma patent practice, the most important prior art reference is often not a patent at all. It is a paper in a peer-reviewed journal, a clinical trial registration, a conference abstract, or a regulatory submission....
Introduction US patent teams in 2026 are fighting on two fronts simultaneously. In prosecution, Section 101 Alice rejections continue to be the most common final rejection for software and AI patent applications — affecting more than 40% of applications in...
Introduction India is the world’s third-largest pharmaceutical patent filer. Its technology sector — centred in Bangalore, Hyderabad, and Pune — is generating an accelerating volume of software, semiconductor, and AI patent applications. Its regulatory environment for patent prosecution has undergone...
A granted patent is a starting point, not a finish line. The most defensible IP positions are built from patent families — parent patents extended through continuations and continuation-in-part applications that follow technology development and block competitive workarounds. Most companies...